Background: A new method of immune-based therapies has been made and applied on multiple sclerosis patients in last decades. Some of these treatments have a high efficacy and reasonable side effects. In slowing disease progression, present treatments have significant limitations, but often associated with significant adverse effects of immunosuppression, with having a bit low capability to counter the disability. Methods: This is a review meta-analysis of treatment of multiple sclerosis. Results: Thus a valuable aim for multiple sclerosis clinical research is to introduce more effective therapies. Conclusion: It is absolutely necessary to increase the individualized therapy planes development in respect to make better planes to disease-modifying treatments.
Seto, S., Carrera, C.J., Kubota, M., Wasson, D.B. and Carson, D.A. (1985) Mechanism of Deoxyadenosine and 2-Chlorodeoxyadenosine Toxicity to Nondividing Human Lymphocytes. Journal of Clinical Investigation, 75, 37-83. http://dx.doi.org/10.1172/JCI111710
Spurgeon, S., Yu, M., Phillips, J.D. and Epner, E.M. (2009) Cladribine: Not Just Another Purine Analogue? Expert Opinion on Investigational Drugs, 18, 1169-1181. http://dx.doi.org/10.1517/13543780903071038
Beutler, E., Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R. and Zyroff, J. (1996) The Treatment of Chronic Progressive Multiple Sclerosis with Cladribine. Proceedings of the National Academy of Sciences of the United States of America, 93, 1716-1720. http://dx.doi.org/10.1073/pnas.93.4.1716
Rice, G.P., Filippi, M. and Comi, G. (2000) Cladribine and Progressive MS: Clinical and MRI Outcomes of a Multicenter Controlled Trial. Cladribine MRI Study Group. Neurology, 54, 1145-1155. http://dx.doi.org/10.1212/WNL.54.5.1145
Romine, J.S., Sipe, J.C., Koziol, J.A., Zyroff, J. and Beutler, E. (1999) A Double-Blind, Placebo-Controlled, Randomized Trial of Cladribine in Relapsing-Remitting Multiple Sclerosis. Proceedings of the Association of American Physicians, 111, 35-44. http://dx.doi.org/10.1046/j.1525-1381.1999.09115.x
Serono, E. (2014) CLARITY: A Phase III, Randomized, Double-Blind, Three-Arm, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects with Relapsing-Remitting Multiple Sclerosis. NCT00213135.
Coles, A.J., Compston, D.A., Selmaj, K.W., et al. (2008) Alemtuzumab vs Interferon Beta-1a in Early Multiple Sclerosis. The New England Journal of Medicine, 359, 1786-1801. http://dx.doi.org/10.1056/NEJMoa0802670
Hauser, S.L., Waubant, E., Arnold, D.L., et al. (2008) B-Cell Depletion with Rituximab in Relapsing-Remitting Multiple Sclerosis. The New England Journal of Medicine, 358, 676-688. http://dx.doi.org/10.1056/NEJMoa0706383
Hawker, K., O’Connor, P., Freedman, M.S., et al. (2009) Rituximab in Patients with Primary Progressive Multiple Sclerosis: Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial. Annals of Neurology, 66, 460-471. http://dx.doi.org/10.1002/ana.21867
Genentech, H.L.R. (2011) Phase II, Multicenter, Randomized, Parallel-Group, Partially Blinded, Placebo and Avonex Controlled Dose Finding Study to Evaluate the Efficacy as Measured by Brain MRI Lesions, and Safety of 2 Dose Regimens of Ocrelizumab in Patients with RRMS. NCT00676715.
Bielekova, B., Catalfamo, M., Reichert-Scrivner, S., et al. (2006) Regulatory CD56 (Bright) Natural Killer Cells Mediate Immunomodulatory Effects of IL-2R Alpha-Targeted Therapy (Daclizumab) in Multiple Sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 103, 5941-5946. http://dx.doi.org/10.1073/pnas.0601335103
Bielekova, B., Richert, N., Howard, T., et al. (2004) Humanized Anti-CD25 (Daclizumab) Inhibits Disease Activity in Multiple Sclerosis Patients Failing to Respond to Interferon Beta. Proceedings of the National Academy of Sciences of the United States of America, 101, 8705-8708. http://dx.doi.org/10.1073/pnas.0402653101
Bielekova, B., Howard, T., Packer, A.N., et al. (2009) Effect of Anti-CD25 Antibody Daclizumab in the Inhibition of Inflammation and Stabilization of Disease Progression in Multiple Sclerosis. Archives of Neurology, 66, 483-489. http://dx.doi.org/10.1001/archneurol.2009.50
Viglietta, V., Bourcier, K., Buckle, G.J., et al. (2008) CTLA4Ig Treatment in Patients with Multiple Sclerosis: An Open-Label, Phase 1 Clinical Trial. Neurology, 71, 917-924. http://dx.doi.org/10.1212/01.wnl.0000325915.00112.61
Mehling, M., Brinkmann, V., Antel, J., et al. (2008) FTY720 Therapy Exerts Differential Effects on T Cell Subsets in Multiple Sclerosis. Neurology, 71, 1261-1267. http://dx.doi.org/10.1212/01.wnl.0000327609.57688.ea
Brinkmann, V. (2009) FTY720 (Fingolimod) in Multiple Sclerosis: Therapeutic Effects in the Immune and the Central Nervous System. British Journal of Pharmacology, 158, 1173-1182. http://dx.doi.org/10.1111/j.1476-5381.2009.00451.x
Novartis (2014) TRANSFORMS FTY720. A 12-Month Study Comparing the Efficacy and Safety of Two Doses of Fingolimod versus Interferon β-1a in Patients with Relapsing-Remitting Multiple Sclerosis with Optional Extension Phase. NCT00340834.
GlaxoSmithKline (2012) Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and the Safety of Six Months’ Administration of SB-683699 in Subjects with Relapsing-Remitting Multiple Sclerosis. NCT00395317.
Comi, G., Pulizzi, A., Rovaris, M., et al. (2008) Effect of Laquinimod on MRI-Monitored Disease Activity in Patients with Relapsing-Remitting Multiple Sclerosis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase IIb Study. The Lancet, 371, 2085-2092. http://dx.doi.org/10.1016/S0140-6736(08)60918-6
Teva Pharmaceutical Industries (2016) A Multinational, Multicenter, Open-Label, Single-Assignment Extension of the MS-LAQ-301 Study, to Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course of Daily Oral Laquinimod 0.6 mg in Subjects with Relapsing Multiple Sclerosis. NCT00988052.
De Jong, R., Bezemer, A.C., Zomerdijk, T.P., van de Pouw-Kraan, T., Ottenhoff, T.H. and Nibbering, P.H. (1996) Selective Stimulation of T Helper 2 Cytokine Responses by the Anti-Psoriasis Agent Monomethyl Fumarate. European Journal of Immunology, 26, 2067-2074. http://dx.doi.org/10.1002/eji.1830260916
Wierinckx, A., Breve, J., Mercier, D., Schultzberg, M., Drukarch, B. and Van Dam, A.M. (2005) Detoxication Enzyme Inducers Modify Cytokine Production in Rat Mixed Glial Cells. Journal of Neuroimmunology, 166, 132-143. http://dx.doi.org/10.1016/j.jneuroim.2005.05.013
Schimrigk, S., Brune, N., Hellwig, K., et al. (2006) Oral Fumaric Acid Esters for the Treatment of Active Multiple Sclerosis: An Open-Label, Baseline-Controlled Pilot Study. European Journal of Neurology, 13, 604-610. http://dx.doi.org/10.1111/j.1468-1331.2006.01292.x
Korn, T., Magnus, T., Toyka, K. and Jung, S. (2004) Modulation of Effector Cell Functions in Experimental Autoimmune Encephalomyelitis by Leflunomide—Mechanisms Independent of Pyrimidine Depletion. Journal of Leukocyte Biology, 76, 950-960. http://dx.doi.org/10.1189/jlb.0504308
Sanofi-Aventis (2016) Long-Term Extension of the Multinational, Double-Blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients with Multiple Sclerosis with Relapses. NCT00803049.
Sanofi-Aventis (2012) A Randomized, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks when Added to Treatment with Glatiramer Acetate in Subjects with Multiple Sclerosis. NCT00475865.
Sanofi-Aventis (2012) A Randomized, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks when Added to Treatment with Interferon-Beta in Subjects with Multiple Sclerosis. NCT00489489.
Sanofi-Aventis (2016) An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7 mg Once Daily and 14 mg Once Daily versus Placebo in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis. NCT00622700.
Eli Lilly and Company (2010) An Open Label Follow-On Study to Assess the Ongoing Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis. NCT00870155.
Eli Lilly and Company (2010) A Double-Blind, Placebo Controlled Multicentre Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis. NCT00869726.
Centocor, I. (2012) A Phase II, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Study of Multiple Subcutaneous Injections of Human Monoclonal Antibody to IL-12 p40 (CNTO1275) in Subjects with Relapsing-Remitting Multiple Sclerosis. NCT00207727.
EMD Serono (2016) An Open-Label, Multicenter Phase II Extension of Study 28063 (ATAMS) to Obtain Long-Term Follow-Up Data in Subjects with Relapsing Multiple Sclerosis Treated with Atacicept for up to 5 Years (ATAMS-Extension). NCT00853762.
Karnezis, T., Mandemakers, W., McQualter, J.L., et al. (2004) The Neurite Outgrowth Inhibitor Nogo A Is Involved in Autoimmune-Mediated Demyelination. Nature Neuroscience, 7, 736-744. http://dx.doi.org/10.1038/nn1261
Liebscher, T., Schnell, L., Schnell, D., et al. (2005) Nogo-A Antibody Improves Regeneration and Locomotion of Spinal Cord-Injured Rats. Annals of Neurology, 58, 706-719. http://dx.doi.org/10.1002/ana.20627
Fontoura, P., Ho, P.P., DeVoss, J., et al. (2004) Immunity to the Extracellular Domain of Nogo-A Modulates Experimental Autoimmune Encephalomyelitis. The Journal of Immunology, 173, 6981-6992. http://dx.doi.org/10.4049/jimmunol.173.11.6981
Mi, S., Miller, R.H., Lee, X., et al. (2005) LINGO-1 Negatively Regulates Myelination by Oligodendrocytes. Nature Neuroscience, 8, 745-751. http://dx.doi.org/10.1038/nn1460
Lee, X., Yang, Z., Shao, Z., et al. (2007) NGF Regulates the Expression of Axonal LINGO-1 to Inhibit Oligodendrocyte Differentiation and Myelination. The Journal of Neuroscience, 27, 220-225. http://dx.doi.org/10.1523/JNEUROSCI.4175-06.2007
Satoh, J., Tabunoki, H., Yamamura, T., Arima, K. and Konno, H. (2007) TROY and LINGO-1 Expression in Astrocytes and Macrophages/Microglia in Multiple Sclerosis Lesions. Neuropathology and Applied Neurobiology, 33, 99-107. http://dx.doi.org/10.1111/j.1365-2990.2006.00787.x
Mi, S., Miller, R.H., Tang, W., et al. (2009) Promotion of Central Nervous System Remyelination by Induced Differentiation of Oligodendrocyte Precursor Cells. Annals of Neurology, 65, 304-315. http://dx.doi.org/10.1002/ana.21581
Rafei, M., Campeau, P.M., Aguilar-Mahecha, A., et al. (2009) Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Inhibiting CD4 Th17 T Cells in a CC Chemokine Ligand 2-Dependent Manner. The Journal of Immunology, 182, 5994-6002. http://dx.doi.org/10.4049/jimmunol.0803962
Pluchino, S., Quattrini, A., Brambilla, E., et al. (2003) Injection of Adult Neurospheres Induces Recovery in a Chronic Model of Multiple Sclerosis. Nature, 422, 688-694. http://dx.doi.org/10.1038/nature01552
Hadassah Medical Organization (2016) Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS). 1872 NCT0078.
The Cleveland Clinic and University Hospital Case Medical Center (2016) A Phase I Study to Assess the Feasibility, Safety, and Tolerability of Autologous Mesenchymal Stem Cell Transplantation in Patients with Relapsing Forms of Multiple Sclerosis. NCT00813969.
Corboy, J.R. and Miravalle, A.A. (2010) Emerging Therapies for Treatment of Multiple Sclerosis. Journal of Inflammation Research, 3, 53-59. http://dx.doi.org/10.2147/JIR.S6558
Weinstock-Guttman, B., Hagemeier, J., Kavak, K.S., Saini, V., Patrick, K., Ramasamy, D.P., Nadeem, M., Carl, E., Hojnacki, D. and Zivadinov R. (2016) Randomised Natalizumab Discontinuation Study: Taper Protocol May Prevent Disease Reactivation. Journal of Neurology, Neurosurgery & Psychiatry, 1-7.